Oleksandr Kalyuzhniy

List of Publications by Year
in descending order

20 papers	3,871 citations	430874 18 h-index	794594 19 g-index
20 all docs	20 docs citations	20 times ranked	3862 citing authors

#	Article	IF	Citations
1	Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors. Science, 2013, 340, 711-716.	12.6	680
2	Proof of principle for epitope-focused vaccine design. Nature, 2014, 507, 201-206.	27.8	451
3	HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science, 2016, 351, 1458-1463.	12.6	382
4	Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science, 2015, 349, 156-161.	12.6	358
5	HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity, 2016, 45, 483-496.	14.3	335
6	Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. Immunity, 2018, 48, 133-146.e6.	14.3	274
7	Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. Cell, 2016, 166, 1459-1470.e11.	28.9	230
8	Computational Design of Epitope-Scaffolds Allows Induction of Antibodies Specific for a Poorly Immunogenic HIV Vaccine Epitope. Structure, 2010, 18, 1116-1126.	3.3	203
9	A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. Science, 2019, 366, .	12.6	172
10	Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science, 2016, 353, 1557-1560.	12.6	147
11	Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. Nature Communications, 2017, 8, 1655.	12.8	142
12	The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. Science Translational Medicine, 2018, 10, .	12.4	113
13	Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies. Immunity, 2018, 49, 301-311.e5.	14.3	110
14	Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. PLoS Pathogens, 2016, 12, e1005815.	4.7	104
15	Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design. PLoS Pathogens, 2017, 13, e1006212.	4.7	58
16	B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22920-22931.	7.1	42
17	Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6849-E6858.	7.1	38
18	Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. PLoS Pathogens, 2018, 14, e1006986.	4.7	28

#	Article	IF	Citations
19	Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer. Cell Reports, 2022, 38, 110485.	6.4	4
20	Highly Mutated Antibodies Capable of Neutralizing N276-Glycan Deficient HIV after a Single Immunization with an Env Trimer. SSRN Electronic Journal, 0, , .	0.4	0